Recombinant CD19 (Inebilizumab Biosimilar) antibody
Research Grade
Reactivity: Human
Host: Humanized
Chimeric
unconjugated
Recombinant Antibody
-
- Target See all CD19 (Inebilizumab Biosimilar) products
- CD19 (Inebilizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Humanized
- Expression System
- Mammalian cells
-
Clonality
- Chimeric
-
Conjugate
- This CD19 (Inebilizumab Biosimilar) antibody is un-conjugated
- Application
- Please inquire
- Purpose
- Research Grade Inebilizumab Biosimilar Antibody
- Specificity
- CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
- Purification
- Protein A or G purified from cell culture supernatant.
- Purity
- >95 % by SDS-PAGE.
- Grade
- Research Grade
- Isotype
- IgG1 kappa
-
-
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1.31 mg/mL
- Buffer
- 0.01M PBS, pH 7.4.
- Storage
- 4 °C,-20 °C,-80 °C
- Storage Comment
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
- Expiry Date
- 12 months
-
- Target
- CD19 (Inebilizumab Biosimilar)
- Alternative Name
- Inebilizumab Biosimilar (CD19 (Inebilizumab Biosimilar) Products)
- Target Type
- Biosimilar
- Background
- CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
- UniProt
- P15391
- CAS-No
- 1299440-37-1
-
You are here:
